

1 **Title Page**

2 *Association between sleep and seroconversion after*
3 *vaccination with inactivated SARS-CoV-2 in pregnant*
4 *women*

5
6 Xue Han^{1,2}, Wenhan Yang¹, Xi Zhang^{1,2}, Baolan Chen^{1,2}, Xi Fu¹, Jitian
7 Huang^{1,2}, Yingxia Xu^{1,2}, Yajie Gong^{1,2*}, Qingsong Chen^{1,2*}

8
9 ¹School of Public Health, Guangdong Pharmaceutical University,
10 Guangzhou, China.

11 ²NMPA Key Laboratory for Technology Research and Evaluation of
12 Pharmacovigilance, Guangzhou, China.

13
14 ***Corresponding Author:**

15 1.E-mail:qingsongchen@aliyun.com(QSC)

16 2.E-mail:gongyajie2016@163.com(YJG)

17

18

19

20

21

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 **Abstract**

23 To assess the association between sleep and seroconversion after
24 receipt of two doses of inactivated severe acute respiratory
25 syndrome-coronavirus-2 (SARS-CoV-2) vaccines in pregnant women.
26 The serum level of immunoglobulin (Ig)G antibodies against the nucleic
27 acids of SARS-CoV-2 was measured. Logistic regression was used to
28 analyze the association between sleep and seroconversion. After two doses
29 of SARS-CoV-2 vaccine, 41.2% of the study cohort reached
30 seroconversion. Analysis revealed that pregnant women with poor quality
31 of sleep had a lower serum level of IgG antibodies ($P = 0.008$, 95%CI =
32 0.285–0.826) and that sleeping late at night (SLaN) may be a risk factor for
33 a low serum level of IgG antibodies ($P = 0.025$, 95%CI = 0.436–0.946).
34 Besides sleep, age and the time since vaccination were important
35 influences on seroconversion. A stratified analysis revealed that the effects
36 of sleep quality and SLaN on seroconversion occurred mainly in pregnant
37 women aged <35 years. Thus, sleep quality and SLaN can affect the serum
38 level of IgG antibodies in pregnant women after vaccination with
39 inactivated SARS-CoV-2.

40

41 **Introduction**

42 The coronavirus disease-2019 (COVID-19) pandemic was once an
43 important public-health issue worldwide despite aggressive government

44 responses. Mass vaccination is a key measure to control the spread of this
45 outbreak. Dozens of severe acute respiratory syndrome-coronavirus
46 disease-2 (SARS-CoV-2) vaccines have been approved for use, with >1.2
47 billion doses administered worldwide as of August 2022^[1]. Countries used
48 to adopt home-quarantine methods to control the spread of COVID-19, in
49 addition to large-scale vaccination.

50 The symptoms of COVID-19 infection and the side effects of
51 vaccination may lead to sleep problems, but whether it is also related to
52 other factors of the vaccine is unknown. Sleep is a state of total rest and
53 active neuromodulation of the central nervous system required by the body
54 to eliminate fatigue. Several studies have shown that sleep can be involved
55 (directly or indirectly) in regulation of the immune system through its
56 effects on the nervous system and neuroendocrine system^[2,3]. Maintenance
57 of many immune functions is dependent on circadian rhythms and regular
58 sleep. Sleep can affect various components of the immune system, and
59 sleep disturbance can cause changes in the number and function of
60 immune cells.

61 Clinical findings have shown that sleep deprivation affects expression
62 of proinflammatory factors in central and peripheral systems in humans.
63 Five nights of sleep restriction has been shown to increase circulating
64 levels of the proinflammatory factors interleukin (IL)-1 β , IL-6, and IL-17,
65 which remain at high levels even after 2 nights of sleep recovery^[4]. In a

66 prospective cohort study from Greece, in which all enrolled participants
67 received two doses of a vaccine based on mRNA SARS-CoV-2, insomnia
68 was found to be associated with a lower serum level of immunoglobulin
69 (Ig)G antibodies, but that study did not involve pregnant women^[5].

70 Physiological changes during pregnancy have significant effects on
71 the immune system and respiratory system. The effect on the immune
72 system after vaccination is influenced by various factors. However, few
73 studies have investigated the effect of sleep on the immune system of
74 pregnant women after administration of a vaccine based on inactivated
75 SARS-CoV-2.

76 Here, we investigated the effect of sleep on the serum level of IgG
77 antibodies in pregnant women after receipt of two doses of inactivated
78 SARS-CoV-2 vaccine.

79 **Methods**

80 **Study design**

81 We collected information from the electronic medical records of
82 pregnant women who gave birth in three hospitals in Guangzhou from
83 December 2021 to March 2022. These women were given questionnaires
84 to complete. All participants provided written informed consent. The study
85 protocol complied with the Declaration of Helsinki 1964 and its later
86 amendments. The data they provided included demographic information
87 as well as information on basic behavioral lifestyle, including marital

88 status, educational level, occupation, age (stratified by the advanced
89 maternal age defined by the World Health Organization), body mass index,
90 time of last menstruation, sleep status (duration of nighttime sleep,
91 “napping”, sleeping late at night (defined as go to bed past 11 p.m, SLaN),
92 sleep disturbance, sleep quality), tobacco smoking, alcohol consumption,
93 pregnancy, disease history, and the time since vaccination (defined as the
94 time interval between the last dose of vaccine and blood collection) .

95 To exclude the effect of different doses of vaccine on the serum level
96 of IgG antibodies, only pregnant women who received two doses of
97 inactivated SARS-CoV-2 vaccine were included in this study. Pregnant
98 women who had been infected or were infected with SARS-CoV-2 after
99 enrollment and who received non-inactivated vaccine were excluded.

100 **Collection and analyses of samples**

101 After enrollment, 5 mL of venous blood was collected, centrifuged to
102 separate the serum, and stored at -80°C . IgG antibodies against the nucleic
103 acids of SARS-CoV-2 were detected using a chemiluminescence kit
104 (Bioscience, Chongqing, China). A serum level of IgG antibodies <1.00
105 signal/cutoff (S/CO) ratio was considered negative. A serum level of IgG
106 antibodies ≥ 1.00 S/CO was considered positive.

107 **Statistical analyses**

108 Descriptive analysis was used to denote demographic features. Factors
109 that may affect the serum level of IgG antibodies were identified using the

110 chi-squared test or rank-sum test. Logistic regression analysis was
111 employed to analyze the relationship between sleep-related factors and
112 antibody positivity. Statistical analyses were undertaken using SPSS 25.0
113 (IBM, Armonk, NY, USA). $P < 0.05$ (two-sided) was considered
114 significant.

115 **Results**

116 **Demographic and clinical characteristics**

117 The study cohort comprised 650 pregnant women aged 18–43 years
118 who had received two doses of inactivated SARS-CoV-2 vaccine before or
119 during pregnancy. The number of pregnant women who had two doses of
120 SARS-CoV-2 vaccine before and during pregnancy was 544 (83.7%) and
121 106 (16.3%), respectively.

122 A total of 440 (67.6%) pregnant women had suffered from a sleep
123 disturbance in the previous year. These sleep disturbance included:
124 difficulty in falling asleep (unable to fall asleep within 30 min); awakening
125 readily or early at night; frequent visits to the toilet at night; nightmares;
126 excessive dreaming. Seventy-nine pregnant women were aged >35 years
127 (12.1%) (**Table 1**).

Table 1. Demographic characteristics of participants

Characteristic	Total (N = 650)	Sleep disturbance		<i>P</i>	Sleeping late at night		<i>P</i>	Napping		<i>P</i>
		Yes (N = 440)	No (N = 210)		Yes (N = 480)	No (N = 170)		Yes (N = 473)	No (N = 177)	
Age, years				0.238			0.857			0.683
<35	571 (87.8)	382 (86.8)	189 (90.0)		421 (87.7)	150 (88.2)		414 (87.5)	157 (88.7)	
≥35	79 (12.2)	58 (13.2)	21 (10.0)		59 (12.3)	20 (11.8)		59 (12.5)	20 (11.3)	
BMI, kg/m²				0.276			0.686			0.589
<18.5	122 (18.8)	80 (18.2)	42 (20.0)		89 (18.5)	33 (19.4)		94 (19.9)	28 (15.8)	
18.5–23.9	394 (60.6)	267 (60.7)	127 (60.5)		297 (61.9)	97 (57.1)		281 (59.4)	113 (63.8)	
≥24	134 (20.6)	93 (21.1)	41 (19.5)		94 (19.6)	40 (23.5)		98 (20.7)	36 (20.4)	
Education				0.496			0.903			<0.001
Secondary school and below	297 (45.7)	197 (44.8)	100 (47.6)		220 (45.8)	77 (45.3)		195 (41.2)	102 (57.6)	
College or above	353 (54.3)	243 (55.2)	110 (52.4)		260 (54.2)	93 (54.7)		278 (58.8)	75 (42.4)	
Occupation				0.404			0.815			0.032
Part-time or full-time	435 (66.9)	290 (65.9)	145 (69.0)		320 (66.7)	115 (67.6)		328 (69.3)	107 (60.5)	
Unemployed	215 (33.1)	150 (34.1)	65 (31.0)		160 (33.3)	55 (32.4)		145 (30.7)	70 (39.5)	
Marriage				0.472			0.095			0.428
Unmarried, divorced	20 (3.1)	15 (3.4)	5 (2.4)		18 (3.8)	2 (1.2)		13 (2.7)	7 (4.0)	
Married	630 (96.9)	425 (96.6)	205 (97.6)		462 (96.2)	168 (98.8)		460 (97.3)	170 (96.0)	
Tobacco smoking				0.355			0.182			0.520
No	645 (99.2)	437 (99.3)	208 (99.0)		475 (99.0)	170 (100.0)		470 (99.4)	175 (98.9)	
Yes	5 (0.8)	3 (0.7)	2 (1.0)		5 (1.0)	0 (0.0)		3 (0.6)	2 (1.1)	

130 **Table 1. Demographic characteristics of participants**

Characteristic	Total (N = 650)	Sleep disturbance		P	Sleeping late at night		P	Napping		P
		Yes (N = 440)	No (N = 210)		Yes (N = 480)	No (N = 170)		Yes (N = 473)	No (N = 177)	
Alcohol consumption				0.204			0.399			0.386
No	648 (99.7)	439 (99.8)	209 (99.5)		478 (99.6)	170 (100.0)		471 (99.6)	177 (100.0)	
Yes	2 (0.3)	1 (0.2)	1 (0.5)		2 (0.4)	0 (0.0)		2 (0.4)	0 (0.0)	
Disease history^c				0.183			0.472			0.264
No	539 (82.9)	359 (81.6)	180 (85.7)		395 (82.3)	144 (84.7)		397 (83.9)	142 (80.2)	
Yes	111 (17.1)	81 (18.4)	30 (14.3)		85 (17.7)	26 (15.3)		76 (16.1)	35 (19.8)	
Exercise				0.812			0.298			0.014
No	255 (39.2)	174 (39.5)	81 (38.6)		194 (40.4)	61 (35.9)		172 (36.4)	83 (46.9)	
Yes	395 (60.8)	266 (60.5)	129 (61.4)		286 (59.6)	109 (64.1)		301 (63.6)	94 (53.1)	
Time of vaccination^a				0.058			0.062			0.455
Pre-pregnancy	544 (83.7)	360 (81.8)	184 (87.7)		394 (82.1)	150 (88.2)		399 (84.4)	145 (81.9)	
Pregnancy	106 (16.3)	80 (18.2)	26 (12.3)		86 (17.9)	20 (11.8)		74 (15.6)	32 (18.1)	
IgG antibodies to SARS-CoV-2				0.408			0.043			0.168
-	383 (58.9)	254 (57.7)	129 (61.4)		294 (61.3)	89 (52.4)		271 (57.3)	112 (63.3)	
+	267 (41.1)	186 (42.3)	81 (38.6)		186 (38.8)	81 (47.6)		202 (42.7)	65 (36.7)	

Inoculation duration^b, weeks	28.94±6.13	29.03±6.00	28.75±6.40	0.135	29.00±6.25	28.74±5.82	0.357	28.88±6.17	29.08±6.07	0.424
--	------------	------------	------------	-------	------------	------------	-------	------------	------------	-------

132 ^atime of vaccination indicates the time of the last dose.

133 ^bdefined as the time interval between the last dose of vaccine and blood collection.

134 ^chistory of diseases during pregnancy.

135

136 **Relationship between the serum concentration of IgG** 137 **antibodies and sleep**

138 “Seroconversion” is the development of specific antibodies in the blood
139 serum as a result of infection or immunization, including vaccination. We
140 discovered that, after vaccination, 41.2% of pregnant women had produced
141 IgG antibodies against the nucleic acids of SARS-CoV-2. Most of the
142 enrolled pregnant women had the habit of SLaN (73.8%) and taking a nap
143 (72.8%). The duration of nighttime sleep was 8.51 ± 1.14 h and the duration
144 of a single nap was 0.81 ± 0.81 h. Univariate analysis revealed a significant
145 difference between education level, occupation, and exercise status and
146 napping ($P < 0.05$). A significant difference between the prevalence of
147 SLaN and production of IgG antibodies was documented ($P =$
148 0.043)(**Table 1**).

149 Logistic regression analysis revealed a significant difference between
150 sleep quality, SLaN, and production of IgG antibodies ($P < 0.05$)(**Table 2**).
151 We discovered that the prevalence of seroconversion was lower in
152 pregnant women who had poor quality of sleep ($P = 0.008$, 95%CI
153 $0.285-0.826$) and that SLaN may be a risk factor for low production of IgG
154 antibodies in pregnant women ($P = 0.025$, 95%CI $0.436-0.946$), which

155 persisted even after adjustment for confounders. In addition to the
 156 significant difference between sleep factors and production of IgG
 157 antibodies, age ($P = 0.016$, 95%CI 0.307–0.885) and the time since
 158 vaccination (defined as the time interval between the last dose of vaccine
 159 and blood collection) ($P < 0.001$, 95%CI 0.912–0.967) were associated
 160 with seroconversion.

161

162 **Table 2. Multifactorial logistic regression analysis of antibody positivity**

Characteristic	IgG antibodies to SARS-CoV-2	
	OR (95%CI) ^a	<i>P</i>
Age group, years		
<35	1.00	
≥35	0.522 (0.307–0.885)	0.016
Inoculation duration, weeks	0.939 (0.912–0.967)	<0.001
Sleep quality		
Good	1.00	
Poor	0.485 (0.285–0.826)	0.008
Duration of nighttime sleep, h		
<8	1.00	
≥8	0.774 (0.535–1.119)	0.173
Sleep disturbance	1.332 (0.932–1.903)	0.116
Napping	1.257 (0.862–1.834)	0.234
Sleeping late at night	0.642 (0.436–0.946)	0.025

163 OR, odds ratio; 95% CI, 95% confidence interval.

164 ^aAdjusted for BMI, education, occupation, tobacco smoking, alcohol consumption, exercise, time
 165 of vaccination, history of diseases during pregnancy.

166

167

168 For the further exploring the differences between SLaN, sleep quality,
169 and the serum level of IgG antibodies in pregnant women of different age
170 groups and at the time since vaccination, a stratified analysis was
171 conducted within two groups: pregnant women aged 35 years (**Table 3**);
172 24 weeks after vaccination (**Table 4**). The effects of sleep quality and
173 SLaN on the serum level of IgG antibodies in pregnant women were found
174 mainly in the group younger than 35 years. No relationship between sleep
175 quality, SLaN, and the serum level of IgG antibodies was found in the
176 group vaccinated <24 weeks previously. However, in the group vaccinated
177 >24 weeks previously, there was an association between SLaN and the
178 serum level of IgG antibodies, but not significantly so ($P = 0.053$).

179 **Table 3. Association between pregnancy, sleep, and antibody level by age**

Group	IgG antibodies to SARS-CoV-2	
	OR (95%CI)	<i>P</i>
<35, years		
Sleeping late at night	0.618 (0.421–0.908)	0.014
Poor quality of sleep	0.531 (0.308–0.917)	0.023
≥35, years		
Sleeping late at night	2.189 (0.629–7.615)	0.218
Poor quality of sleep	0.743 (0.168–3.277)	0.694

180 OR, odds ratio; 95% CI, 95% confidence interval.

182 **Table 4. Association between pregnancy, sleep, and antibody level according to**
183 **the time since vaccination**

Group	IgG antibodies to SARS-CoV-2	
	OR (95%CI)	<i>P</i>
<24 weeks		
Sleeping late at night	0.758 (0.307–1.872)	0.548
Poor sleep quality	0.412 (0.148–1.146)	0.089
≥24 weeks		
Sleeping late at night	0.676 (0.455–1.005)	0.053
Poor quality of sleep	0.635 (0.351–1.148)	0.133

184 OR, odds ratio; 95% CI, 95% confidence interval.

185

186 **Discussion**

187 Vaccination using inactivated SARS-CoV-2 is an effective measure
188 to prevent SARS-CoV-2 infection. China, with its large population,
189 provides an opportune study site for assessing vaccination using
190 inactivated SARS-CoV-2 in pregnant women. To our knowledge, this is
191 the first study to investigate the association of sleep status and
192 seroconversion after vaccination using inactivated SARS-CoV-2 in
193 pregnant women. The present study found sleep status was found to be
194 associated with serum level of IgG antibodies.

195 To explore the impact of sleep status on antibody levels in pregnant
196 women after vaccination against SARS-CoV-2 is a rational approach.
197 Physical discomfort, anxiety, or hormonal changes caused by pregnancy

198 can lead to sleeping problems in pregnant women^[17]. Studies have shown
199 that disruption of sleep patterns leads to endocrine disorders and changes
200 in the balance of the immune system, including changes in the number of
201 immune cells and cytokine levels in peripheral blood. This phenomenon
202 results in reduced immune defense against, and increased susceptibility to,
203 pathogens^[6], which increases the risk of SARS-CoV-2 infection in
204 pregnant women. Which was similar to our findings that pregnant women
205 with poor quality of sleep or SLaN had a lower serum level of IgG
206 antibodies.

207 The level of the immune response after vaccination is influenced by
208 different factors, including vaccine dose and age, which may have a
209 significant impact on the efficacy and duration of vaccine protection.
210 However, few studies have explored the effect of sleep on the immune
211 response after vaccination with inactivated SARS-CoV-2. In the present
212 study, poor sleep quality was found to be a risk factor for the serum level of
213 IgG antibodies, a finding consistent with that of other vaccine-related
214 studies. In a large-sample cohort study, all participants received two doses
215 of the mRNA SARS-CoV-2 vaccine, but pregnant women were excluded.
216 That study found that poor quality of sleep was associated negatively with
217 antibody levels^[5].

218 Observations on the immune response to vaccines and the
219 relationship with sleep arose originally from animal studies. Brown and

220 colleagues found that clearance of the influenza virus was slowed in
221 sleep-deprived mice compared with that in mice with a normal sleeping
222 pattern^[7]. Clinical research on sleep and the immune response to
223 vaccination has focused on vaccines against influenza, hepatitis, and
224 *Salmonella* Typhi. A study of a healthy population aged 40–60 years who
225 received three doses of hepatitis-B vaccine revealed that a short duration of
226 sleep was strongly associated with the likelihood of a reduced serum level
227 of antibodies to the hepatitis-B vaccine. Also, this negative effect of sleep
228 disturbance persisted even if triple doses of the vaccine were given, as well
229 as a 6-month adjuvant dose^[8]. A study of the immune effect of influenza
230 vaccination in college students revealed that poor quality of sleep may be a
231 risk factor for reduced immunity to an influenza virus^[13]. Appropriately
232 prolonged nighttime sleep after vaccination promotes host immune
233 responses^[14,15], and serum-specific antibody concentrations have been
234 found to be significantly lower in sleep-deprived men 5 days after
235 vaccination with the influenza A (H1N1) virus compared with those in a
236 group with a normal sleeping pattern^[9]. Similarly, people who had a
237 regular sleeping pattern after Hepatitis A virus vaccination had higher
238 antibody titers after 4 weeks^[10]. One study found that 10 days after
239 vaccination with a seasonal influenza virus, individuals who had 4
240 consecutive nights of sleep restricted to 4 h had IgG antibody titers less
241 than half that of individuals without this sleep deficit^[16].

242 The body has a “biological clock” to maintain the rhythm of sleep,
243 and SLaN can disrupt this rhythm and affect sleep quality. A recent study
244 showed that frequent SLaN greatly disrupted the ratio of immune cells, and
245 that this alteration contributed to a reduction in the function of immune
246 cells^[18]. In the present study, SLaN was found to be an independent
247 influence on the serum level of IgG antibodies in pregnant women, with
248 those who SLaN habitually having a lower serum level of IgG antibodies.
249 In addition, the effect of poor sleep quality and SLaN on the serum level of
250 IgG antibodies was found mainly in women aged <35 years. This finding
251 may have been due to the fact that older pregnant women pay more
252 attention to the regularity of their work-and-rest schedule because their
253 body functions decline with age. Napping can reduce drowsiness and may
254 have some benefits for mood stability and cognitive function. An
255 association between napping and antibody levels has been documented,
256 but this finding did not hold after adjustment for confounding factors ^[5],
257 which is similar to our findings.

258 We also identified significant differences between age, time since
259 vaccination, and the serum level of IgG antibodies in pregnant women who
260 received two doses of inactivated SARS-CoV-2 vaccine. Age was an
261 important factor maybe to influencing the serum level of IgG antibodies,
262 and that positivity to IgG antibodies was lower in older pregnant women.
263 A phase-II clinical trial of the CoronaVac vaccine involving 600 healthy

264 adults (18-59 years) revealed that levels of neutralizing antibodies
265 decreased with increasing age^[11]. Similarly, another study found that the
266 level of the immune response in pregnant women who received an mRNA
267 vaccine was correlated negatively with maternal age^[12]. Antibody levels in
268 people decrease over time after completing vaccination. One study
269 revealed that antibody levels were correlated negatively with time, and
270 approached the threshold of seropositivity 6 months after receipt of two
271 doses of a vaccine ^[11].

272 This was the first study to analyze the effect of sleep status on the
273 immune response of pregnant women after vaccination with inactivated
274 SARS-CoV-2 based on real-world data in three hospitals in China.
275 However, we declare some limitation in present study. This is a real-world
276 study, which cannot be designed as precisely as a clinical trial. Therefore,
277 data quality may vary widely. Future prospective cohorts with large
278 samples may be needed to further validate the relationship between sleep
279 and the effects of immunization using vaccines.

280 **Conclusions**

281 Sleep quality and SLaN can affect the serum level of IgG antibodies
282 in pregnant women after vaccination with inactivated SARS-CoV-2.

283 **Acknowledgments**

284 The authors would like to acknowledge and thank for all people's
285 contributions during the early stages of the work on this manuscript.

286 **References**

- 287 [1] World Health Organization. Coronavirus disease (COVID-19) Dashboard 2022.
288 Available from <https://covid19.who.int/?mapFilter=vaccinations>. Cited 2022
289 August.
- 290 [2] Dengler V, Westphalen K, Koeppen M. Disruption of circadian rhythms and sleep
291 in critical illness and its impact on innate immunity[J]. *Curr Pharm Des*, 2015,
292 21(24): 3469-3476. doi: 10.2174/1381612821666150706105034.
- 293 [3] Man K, Loudon A, Chawla A. Immunity around the clock[J]. *Science*, 2016,
294 354(6315): 999-1003. doi: 10.1126/science.aah4966.
- 295 [4] Ruiz FS, Andersen ML, Martins RC, Zager A, Lopes JD, Tufik S.. Immune
296 alterations after selective rapid eye movement or total sleep deprivation in
297 healthy male volunteers[J]. *Immun*, 2012,18(1): 44-54. doi:
298 10.1177/1753425910385962.
- 299 [5] Athanasiou N, Baou K, Papandreou E, et al. Association of sleep duration and
300 quality with immunological response after vaccination against severe acute
301 respiratory syndrome coronavirus-2 infection. *J Sleep Res*. 2023 Feb; 32(1):
302 e13656. doi: 10.1111/jsr.13656.
- 303 [6] Lungato L, Gazarini ML, Paredes-Gamero EJ, et al. Paradoxical sleep deprivation
304 impairs mouse survival after infection with malaria parasites[J]. *Malar J*, 2015,
305 14: 183. doi: 10.1186/s12936-015-0690-7.
- 306 [7] Brown R, Pang G, Husband AJ, King MG. Suppression of immunity to influenza
307 virus infection in the respiratory tract following sleep disturbance[J]. *Reg*

- 308 Immunol, 1989, 2(5): 321-325.
- 309 [8] Prather AA, Hall M, Fury JM, Ross DC, Muldoon MF, Cohen S, et al. Sleep and
310 antibody response to hepatitis B vaccination[J], Sleep, 2012, 35(8): 1063-1069.
311 doi: 10.5665/sleep.1990.
- 312 [9] Benedict C, Brytting M, Markstrm A, Broman JE, Schiöth HB. Acute sleep
313 deprivation has no lasting effects on the human antibody titer response following
314 a novel influenza A H1N1 virus vaccination[J]. BMC Immunol, 2012 Jan 4;13:1.
315 doi: 10.1186/1471-2172-13-1.
- 316 [10] Lange T, Perras B, Fehm HL, Born J. Sleep enhances the human antibody
317 response to hepatitis A vaccination[J]. Psychosom Med, 2003, 65(5): 831-835.
318 doi: 10.1097/01.
- 319 [11] Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, et al. Immunogenicity and safety
320 of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in
321 healthy adults: interim results from two single-centre, double-blind, randomised,
322 placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022 Apr;
323 22(4):483-495. doi: 10.1016/S1473-3099(21)00681-2.
- 324 [12] Kugelman N, Nahshon C, Shaked-Mishan P, Cohen N, Sher ML, Gruber M, et al.
325 Maternal and Neonatal SARS-CoV-2 Immunoglobulin G Antibody Levels at
326 Delivery After Receipt of the BNT162b2 Messenger RNA COVID-19 Vaccine
327 During the Second Trimester of Pregnancy. JAMA Pediatr. 2022 Mar 1;
328 176(3):290-295. doi: 10.1001/jamapediatrics.2021.5683.
- 329 [13] Taylor, D. J., Kelly, K., Kohut, M. L., & Song, K. S. (2017). Is insomnia a risk

330 factor for decreased influenza vaccine response? Behavioral Sleep Medicine,

331 15(4), 270-287. <https://doi.org/10.1080/15402002.2015.1126596>.(1)

332 [14] Rayatdoost E, Rahmanian M, Sanie MS, Rahmanian J, Matin S, Kalani N, et al.

333 Sufficient Sleep, Time of Vaccination, and Vaccine Efficacy: A Systematic

334 Review of the Current Evidence and a Proposal for COVID-19 Vaccination.

335 Yale J Biol Med. 2022 Jun 30;95(2):221-235. PMID: 35782481; PMCID:

336 PMC9235253.

337 [15] Prather AA, Pressman SD, Miller GE, Cohen S. Temporal links between

338 selfreported sleep and antibody responses to the influenza vaccine. Int J Behav

339 Med 2021; 28: 151-158. doi: 10.1007/s12529-020-09879-4.

340 [16] Spiegel K, Sheridan JF, Van Cauter E. Effect of sleep deprivation on response to

341 immunization. JAMA 2002; 288: 1471-72. doi: 10.1001/jama.288.12.1471-a.

342 [17] Hall WA, Hauck YL, Carty EM, Hutton EK, Fenwick J, Stoll K. Childbirth fear,

343 anxiety, fatigue, and sleep deprivation in pregnant women. J Obstet Gynecol

344 Neonatal Nurs.2009; 38(5):567-576. doi: 10.1111/j.1552-6909.2009.01054.x.

345 [18] Aiello I, Fedele MLM, Román F, Marpegan L, Caldart C, Chiesa JJ, et al.

346 Circadian disruption promotes tumor-immune microenvironment remodeling

347 favoring tumor cell proliferation. Sci Adv. 2020 Oct 14; 6(42):eaaz4530. doi:

348 10.1126/sciadv.aaz4530.

349